Dendreon drug against prostate cancer covered by Medicare
SAN FRANCISCO (Reuters) – Dendreon Corp. said Thursday that Medicare does now his treatment of prostate cancer Provenge. The drug is the first food and drugs adminstratives approved immunotherapy for prostate cancer for Medicare coverage, according to the Centers for Medicare & Medicaid Services. Dendreon’s shares rose 2.3% to 40.35 dollars in after-hours activity. Market Pulse Stories …
Learn more about
Bites Bullet Medicare to cover Dear Provenge, prostate cancer drugs for serious
July 1, 20 011 – Medicare patients with metastatic prostate cancer can get a first of its kind in its treatment approved by the Food and Drug Administration in April, by a decision of the final cover released yesterday by the Centers for Medicare & amp ; Medicaid Services (CMS). Provenge (sipuleucel-T) have an active patient’s immune system to defend against cancer of the prostate.
Learn more about Journal
Risk prostate cancer and smoking
A recent study published in The Journal of the American Medical Association, men with prostate cancer who smoke have increased prostate cancer-specific mortality compared with non-smokers with prostate cancer. Smokers, were also found to have an increased risk of 61% of cancer recurrence after treatment.
Learn more about PR Newswire via Yahoo Finance
Cancer Health www.newhealthidea.com
You can link to this article on your web site using following code:
We're looking for comments that are interesting, substantial or highly amusing. If your comments are excessively self-promotional (use your real name, no keywords please), obnoxious, or even worse, boring, you will be banned from commenting. Your comment must be related to the post. Please do not comment on how great or wonderful the post is. All comments are moderated and, if approved, will display in less than 24 hours.